Xenetic Biosciences (XBIO) investor relations material

Executive summary

• Advanced proprietary DNase technology for oncology, with ongoing preclinical and clinical development targeting pancreatic carcinoma, solid tumors, and hematologic cancers, supported by expanded collaborative research and translational data.

• Presented positive preclinical and translational data at ASCO 2026, showing DNase I enhanced CAR T-cell therapy outcomes in hematologic cancer models.

• Initiated a formal strategic review process, considering options such as sale, merger, or business combination to maximize shareholder value.

• No regulatory approvals for drug candidates yet; revenue is derived from legacy PolyXen technology royalties.

Financial highlights

• Revenue for Q2 2026 was $0.7M, up 12% year-over-year; six-month revenue was $1.47M, up 24%.

• Net loss for Q2 2026 was $0.93M, a 35% increase year-over-year; six-month net loss was $1.39M, down 13%.

• R&D expenses decreased 16% in Q2 and 21% for the six months, mainly due to lower manufacturing and consulting costs.

• General and administrative expenses rose 64% in Q2 and 32% for the six months, primarily due to legal costs related to the strategic review.

• Cash at June 30, 2026 was $6.5M, down from $7.9M at year-end 2025; working capital was $5.8M.

Outlook and guidance

• Management expects continued operating losses in the near term but believes current resources are sufficient for at least 12 months.

• Additional capital will be needed long-term to pursue business initiatives; access to capital markets may be volatile.

• Focus remains on advancing systemic DNase program into clinical trials as adjunctive therapy for pancreatic carcinoma and advanced solid tumors.

• Ongoing strategic review process to evaluate long-term opportunities and value creation for patients and shareholders.